48 results on '"Voorhees, Timothy J."'
Search Results
2. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
3. SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
4. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
5. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
6. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.
7. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
8. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
9. Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome
10. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
11. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
12. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome
13. A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report.
14. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
15. Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
16. Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma
17. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome
18. Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD
19. Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
20. Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
21. Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
22. Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?
23. Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients
24. A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
25. Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers
26. Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
27. Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
28. Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma
29. Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
30. Interleukin-23 production in dendritic cells is negatively regulated by protein phosphatase 2A
31. Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach
32. A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma
33. Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy
34. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis
35. Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma
36. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
37. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
38. Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation
39. High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience
40. Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
41. Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
42. Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
43. Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
44. Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
45. Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
46. Understanding
47. lnterleukin-23 production in dendritic cells is negatively regulated by protein phosphatase 2A.
48. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.